Gannex Announces Positive Topline Results from the US Phase I Trial of Drug-Drug Interactions in Healthy Subjects and Pharmacokinetics in Patients with NAFLD for Its THRβ Agonist ASC41 - PRNewswire
Submitted by Anonymous (not verified) on Wed, 09/08/2021 - 00:30
